D8517
Iron–Dextran
95-105 mg/mL (Iron content), solution
Synonym(s):
Ferric hydroxide dextran complex
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
biological source
synthetic
Quality Level
sterility
aseptically filled
assay
95-105 mg/mL (Iron content)
form
solution
contains
0.5% phenol as preservative
composition
Iron, ~100 mg/mL
color
brown
useful pH range
4 - 6.5
storage temp.
room temp
SMILES string
[Fe].[S](=O)(=O)(O)O
InChI
1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)
InChI key
MVZXTUSAYBWAAM-UHFFFAOYSA-N
Application
Iron-Dextran (ferric hydroxide dextran complex) may be used as an intravenous iron delivery preparation. Iron-Dextran may be used to induce iron-overload to study its effects and preventative measures.
Other Notes
To gain a comprehensive understanding of our extensive range of Dextrans for your research, we encourage you to visit our Carbohydrates Category page.
signalword
Danger
hcodes
Hazard Classifications
Carc. 1B - Skin Sens. 1
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Zachariah DeFilipp et al.
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 9(1), 129-132 (2012-08-08)
Iron deficiency is a major postoperative complication of Roux-en-Y gastric bypass surgery. Oral replacement can fail to correct the deficiency. Thus, recourse to parenteral iron administration might be necessary. Our objective was to evaluate the effectiveness and safety of a
Markus R Jahn et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 78(3), 480-491 (2011-03-29)
The treatment of iron deficiency anemia with polynuclear iron formulations is an established therapy in patients with chronic kidney disease but also in other disease areas like gastroenterology, cardiology, oncology, pre/post operatively and obstetrics' and gynecology. Parenteral iron formulations represent
Priya Prakash Karmali et al.
Molecular pharmaceutics, 9(3), 539-545 (2012-01-17)
Premature recognition and clearance of nanoparticulate imaging and therapeutic agents by macrophages in the tissues can dramatically reduce both the nanoparticle half-life and delivery to the diseased tissue. Grafting nanoparticles with hydrogels prevents nanoparticulate recognition by liver and spleen macrophages